A guide to cancer immunotherapy: from T cell basic science to clinical practice

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807

Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives

Chen, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.016 · Cited by 43

Mitochondria determine response to anti-programmed cell death protein-1 (anti-PD-1) immunotherapy: An evidence-based hypothesis

Akbari, H., Taghizadeh‐Hesary, F., & Bahadori, M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.12.001 · Cited by 38

Unleashing cell-penetrating peptide applications for immunotherapy

Koo, J., Kim, G., Nam, K.-H., & Choi, J. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.03.010 · Cited by 41

Co‐delivery of dendritic cell vaccine and anti‐PD ‐1 antibody with cryomicroneedles for combinational immunotherapy

Chang, H., Wen, X., Li, Z., Ling, Z., Zheng, Y., & Xu, C. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10457 · Cited by 37

In situ self-assembled nanomedicines for cancer treatment

Sun, X., Yang, X., Chen, Y., Sun, J., He, Z., Zhang, S., & Luo, C. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.143365 · Cited by 38

Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines

Hargrave, A., Mustafa, A. S., Hanif, A., Tunio, J. H., & Hanif, S. N. M. (2023) · Vaccines · doi:10.3390/vaccines11111633 · Cited by 38

PD-1 signaling negatively regulates the common cytokine receptor γ chain via MARCH5-mediated ubiquitination and degradation to suppress anti-tumor immunity

Liu, R., Zeng, L., Li, H.-F., Shi, J.-G., Zhong, B., Shu, H., & Li, S. (2023) · Cell Research · doi:10.1038/s41422-023-00890-4 · Cited by 38

Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy

Bao, Y., Qiao, Y., Choi, J. E., Zhang, Y., Mannan, R., Cheng, C., He, T., Zheng, Y., Yu, J., Gondal, M. N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314416120 · Cited by 39

Surface‐Functionalized Microgels as Artificial Antigen‐Presenting Cells to Regulate Expansion of T Cells

Lou, J., Meyer, C., Vitner, E. B., Adu‐Berchie, K., Dacus, M. T., Bovone, G., Chen, A., To, T., Weitz, D. A., & Mooney, D. J. (2024) · Advanced Materials · doi:10.1002/adma.202309860 · Cited by 39

N-linked glycosylation of PD-L1/PD-1: an emerging target for cancer diagnosis and treatment

Duan, Z., Shi, R., Gao, B., & Cai, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05502-2 · Cited by 47

Surface Molecularly Engineered Mitochondria Conduct Immunophenotype Repolarization of Tumor‐Associated Macrophages to Potentiate Cancer Immunotherapy

Zhang, C., Li, J., Xu, D., Wang, D., Qi, M., Chen, F., Wu, B., Deng, K., & Huang, S. (2024) · Advanced Science · doi:10.1002/advs.202403044 · Cited by 37

CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway

Cao, C., Xu, M., Ye, W., Peng, T., Lin, S., Liu, X., Xu, Y., Chu, T., Liu, S., Wu, P., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100659 · Cited by 39

Nanomedicine for cancer patient‐centered care

Sorrentino, C., Ciummo, S. L., Fieni, C., & Carlo, E. D. (2024) · MedComm · doi:10.1002/mco2.767 · Cited by 43

Metal-based immunogenic cell death inducers for cancer immunotherapy

Zou, J. X., Chang, M. R., Kuznetsov, N. A., Kee, J. X., Babak, M. V., & Ang, W. H. (2025) · Chemical Science · doi:10.1039/d4sc08495k · Cited by 42

Advances in polymer nanomaterials targeting cGAS-STING pathway for enhanced cancer immunotherapy

Peng, S., Hou, X., Liu, J., & Huang, F. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.056 · Cited by 39

ISL Induces Apoptosis and Autophagy in Hepatocellular Carcinoma via Downregulation of PI3K/AKT/mTOR Pathway in vivo and in vitro

Song, L., Luo, Y., Li, S., Hong, M., Wang, Q., Chi, X., & Yang, C. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s270124 · Cited by 38

Astragalus Polysaccharide Injection (PG2) Normalizes the Neutrophil-to-Lymphocyte Ratio in Patients with Advanced Lung Cancer Receiving Immunotherapy

Tsao, S.-M., Wu, T. C., Chen, J., Chang, F.-C., & Tsao, T. C.-Y. (2021) · Integrative Cancer Therapies · doi:10.1177/1534735421995256 · Cited by 38

Establishment of patient‐derived organotypic tumor spheroid models for tumor microenvironment modeling

Hong, H. K., Yun, N. H., Jeong, Y., Park, J., Doh, J., Lee, W. Y., & Cho, Y. B. (2021) · Cancer Medicine · doi:10.1002/cam4.4114 · Cited by 37

Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection

Ferrando‐Martínez, S., Bennett, A. S., Lino, E., Gehring, A. J., Feld, J. J., Janssen, H. L. A., & Robbins, S. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.648420 · Cited by 38

Polymersomes as a potential platform for cancer immunotherapy

Scheerstra, J. F., Wauters, A. C., Tel, J., Abdelmohsen, L. K. E. A., & van Hest, J. C. M. (2021) · Materials Today Advances · doi:10.1016/j.mtadv.2021.100203 · Cited by 41

Stimuli-Responsive Drug Delivery Systems for the Diagnosis and Therapy of Lung Cancer

Xu, L., Wu, J., Liu, Y., Lin, N., Hu, J., & Zhang, B. (2022) · Molecules · doi:10.3390/molecules27030948 · Cited by 38

Engineered stem cells by emerging biomedical stratagems

Wang, J., Zhang, X., Chen, H., Ren, H., Zhou, M., & Zhao, Y. (2024) · Science Bulletin · doi:10.1016/j.scib.2023.12.006 · Cited by 37

Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus

Turchan, W. T., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0145 · Cited by 37

Epigenetically suppressed tumor cell intrinsic STING promotes tumor immune escape

Zheng, H., Wu, L., Xiao, Q., Meng, X., Hafiz, A., Yan, Q., Lu, R., & Cao, J. P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114033 · Cited by 38

In Situ Vaccination Following Intratumoral Injection of IL2 and Poly- l -lysine/Iron Oxide/CpG Nanoparticles to a Radiated Tumor Site

Zhang, Y., Rahman, M. M., Clark, P. A., Sriramaneni, R. N., Havighurst, T. C., Kerr, C. P., Zhu, M., Jones, J., Wang, X., Kim, K., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c00418 · Cited by 37

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

Botta, C., Pérez, C., Larráyoz, M., Puig, N., Cedena, M., Termini, R., Goicoechea, I., Rodríguez, S., Zabaleta, A., López, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41562-6 · Cited by 42

Artificial Intelligence Applications for Biomedical Cancer Research: A Review

Weerarathna, I. N., Kamble, A. R., & Luharia, A. A. (2023) · Cureus · doi:10.7759/cureus.48307 · Cited by 45

Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases

Rana, P. S., Ignatz-Hoover, J. J., & Driscoll, J. J. (2023) · Cancers · doi:10.3390/cancers15235632 · Cited by 40

T-cell dysfunctions in myelodysplastic syndromes

Rodríguez‐Sevilla, J. J., & Colla, S. (2024) · Blood · doi:10.1182/blood.2023023166 · Cited by 37

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

Kamaraj, R., Ghosh, S., Das, S., Sen, S., Kumar, P. R., Majumdar, M., Dasgupta, R., Mukherjee, S., Das, S., Ghose, I., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00253 · Cited by 37

Progression of m6A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming

Han, X., Zhu, Y., Ke, J., Zhai, Y., Huang, M., Zhang, X., He, H., Zhang, X., Zhao, X., Guo, K., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02092-2 · Cited by 40

Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment

Liu, Y., Yang, H., Li, T. X., & Zhang, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1460282 · Cited by 39

Toll-like receptor 3: a double-edged sword

Hsieh, M. L., Nishizaki, D., Adashek, J. J., Kato, S., & Kurzrock, R. (2025) · Biomarker Research · doi:10.1186/s40364-025-00739-5 · Cited by 38

Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy

Venkatraman, S., Meller, J., Hongeng, S., Tohtong, R., & Chutipongtanate, S. (2020) · Vaccines · doi:10.3390/vaccines8040735 · Cited by 36

Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer

Xiao, C., Miller, A. H., Peng, G., Levine, M. E., Conneely, K. N., Zhao, H., Eldridge, R. C., Wommack, E. C., Jeon, S., Higgins, K. A., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.04.002 · Cited by 36

Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy

Shi, H., Li, K., Ni, Y., Liang, X., & Zhao, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707198 · Cited by 39

Multi-organ-on-chip approach in cancer research

Żuchowska, A., & Skorupska, S. (2021) · Organs-on-a-Chip · doi:10.1016/j.ooc.2021.100014 · Cited by 40

Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer

Rossetti, R., Brand, H., de Lima, S. C. G., Furtado, I. P., Silveira, R. M., Fantacini, D. M. C., Covas, D. T., & de Souza, L. E. B. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac005 · Cited by 40

Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types

Willumsen, N., Jensen, C., Green, G. A., Nissen, N. I., Neely, J., Nelson, D. M., Pedersen, R. S., Frederiksen, P., Chen, I. M., Boisen, M. K., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04226-0 · Cited by 37

Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy

Hoeck, J. V., Braeckmans, K., Smedt, S. C. D., & Raemdonck, K. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121510 · Cited by 37

Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies

Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40

Triple‐Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo‐Immunotherapy in Preclinical Cancer Models

Shi, X., Shu, L., Wang, M.-W., Yao, J., Yao, Q., Bian, S., Chen, X., Wan, J., Zhang, F., Zheng, S., et al. (2023) · Advanced Science · doi:10.1002/advs.202204890 · Cited by 36

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Guo, Y., Gao, F., Ahmed, A. R., Rafiq, M., Yu, B., Cong, H., & Shen, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01358h · Cited by 38

Exploiting immunostimulatory mechanisms of immunogenic cell death to develop membrane-encapsulated nanoparticles as a potent tumor vaccine

Liu, Q., Hu, Y., Zheng, P., Yang, Y., Fu, Y., Yang, Y., Duan, B., Wang, M., Li, D., Li, W., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02031-w · Cited by 36

Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy

Xu, F., Jiang, D., Xu, J., Dai, H., Fan, Q., Fei, Z., Wang, B., Zhang, Y., Ma, Q., Yang, Q., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113138 · Cited by 36

B7-H3/CD276 and small-cell lung cancer: What's new?

Fabrizio, F. P., Muscarella, L. A., & Rossi, A. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101801 · Cited by 37

Immunostimulant citrus fruit-derived extracellular vesicle nanodrugs for malignant glioma immunochemotherapy

Li, J., Wang, X., Guo, H., Zhou, H., Sha, S., Yang, Y., Chen, J., Hao, X., Pan, J., Wang, Y., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.149463 · Cited by 36

Urolithin A Hijacks ERK1/2‐ULK1 Cascade to Improve CD8+ T Cell Fitness for Antitumor Immunity

Ma, S., Wu, Q., Wu, W., Tian, Y., Zhang, J., Chen, C., Sheng, X., Zhao, F., Ding, L., Wang, T., et al. (2024) · Advanced Science · doi:10.1002/advs.202310065 · Cited by 40

Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients

Al-Danakh, A., Safi, M., Jian, Y., Yang, L., Zhu, X., Chen, Q., Yang, K., Wang, S., Zhang, J., & Yang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348189 · Cited by 37

Functionalized bioengineered metal-based nanomaterials for cancer therapy

Barabadi, H., Noqani, H., Jounaki, K., Nasiri, A., Karami, K., & Jahani, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15518-5.00024-0 · Cited by 36

CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects

Choudhery, M. S., Arif, T., Mahmood, R., & Harris, D. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113202 · Cited by 40

Dual-Responsive Epigenetic Inhibitor Nanoprodrug Combined with Oncolytic Virus Synergistically Boost Cancer Immunotherapy by Igniting Gasdermin E-Mediated Pyroptosis

Wang, Y., Wang, J., Wang, S., Yang, Q., Song, A., Zhang, M.-J., Wang, W., Liu, Y., Zhang, J., Wang, W.-M., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c03034 · Cited by 37

ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration

Zhang, C., Li, K., Zhu, H., Cheng, M., Chen, S., Ling, R., Wang, C., & Chen, D. (2024) · Nature Communications · doi:10.1038/s41467-024-51096-0 · Cited by 39

The therapeutic potential of bee venom-derived Apamin and Melittin conjugates in cancer treatment: A systematic review

Laurindo, L. F., de Lima, E. P., Laurindo, L. F., Rodrigues, V. D., Chagas, E. F. B., Goulart, R. D. Á., Araújo, A. C., Guiguer, É. L., Pomini, K. T., Rici, R. E. G., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107430 · Cited by 38

NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor progression

Wang, X., Chai, Y., Quan, Y., Wang, J., Song, J., Zhou, W., Xu, X., Xu, H., Wang, B., & Cao, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01618-6 · Cited by 43

Metabolic pathways fueling the suppressive activity of myeloid-derived suppressor cells

Goldmann, O., & Medina, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1461455 · Cited by 42

The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities

Zhang, C., Guo, X., Liu, P., Wang, Y., Zhang, J., Li, L., Wu, K., Xiao, J., Mei, Q., & Wang, Z. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01748-5 · Cited by 43

Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer

Kerr, M. D., McBride, D. A., Chumber, A. K., & Shah, N. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1811673 · Cited by 40

Resveratrol Activates Natural Killer Cells through Akt- and mTORC2-Mediated c-Myb Upregulation

Lee, Y., & Kim, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249575 · Cited by 36

Recent progress in cancer immunotherapy approaches based on nanoparticle delivery devices

Gupta, B., & Kim, J. O. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00527-x · Cited by 37

Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy

Varshney, D., Qiu, S. Y., Graf, T. P., & McHugh, K. J. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00620-x · Cited by 40

TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice

Yıldırım, M., Yildirim, T. C., Turay, N., Bildik, T., İbibik, B., Evcili, İ., Ersan, P. G., Tokat, Ü. M., Şahin, Ö., & Gürsel, İ. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.08.004 · Cited by 36

Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy

Meng, F., Wang, J., & Yeo, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.045 · Cited by 36

Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics

Yang, W., Cao, J., Cheng, H., Chen, L., Yu, M., Chen, Y., & Cui, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.11.014 · Cited by 36

Reprogramming the tumor microenvironment with biotechnology

Kim, M., Lee, N. K., Wang, C. J., Lim, J., Byun, M. J., Kim, T. P., Park, W., Park, D.-H., Kim, S.-N., & Park, C. G. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00343-4 · Cited by 37

NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful

Mauro, A. G., Mezzaroma, E., Toldo, S. A., Meléndez, G. C., Franco, R. L., Lesnefsky, E. J., Abbate, A., Hundley, W. G., & Salloum, F. N. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.004 · Cited by 35

Engineered bacteria for augmented in situ tumor vaccination

Shen, X., Zhu, C., Liu, X., Zheng, H., Wu, Q., Xie, J., Huang, H., Liao, Z., Shi, J., Nan, K., et al. (2023) · Biomaterials Science · doi:10.1039/d2bm01593e · Cited by 35

Covalent organic framework nanoparticles: Overcoming the challenges of hypoxia in cancer therapy

Singh, N., Won, M., Xu, Y., Yoon, C., Yoo, J., Li, M., Kang, H., & Kim, J. S. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215481 · Cited by 35

RNA-based modulation of macrophage-mediated efferocytosis potentiates antitumor immunity in colorectal cancer

Zhou, X., Li, D., Xia, S., Ma, X., Li, R., Mu, Y., Liu, Z., Zhang, L., Zhou, Q., Zhuo, W., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.018 · Cited by 35

A Responsive DNA Hydrogel Containing Poly‐Aptamers as Dual‐Target Inhibitors for Localized Cancer Immunotherapy

Zhang, R., Lv, Z., Chang, L., Wang, J., Tang, J., Wang, Z., Li, S., Guo, J., Yao, C., & Yang, D. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202401563 · Cited by 35

CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors

Liu, J., Jiao, X., Ma, D., Fang, Y., & Gao, Q. (2024) · Med · doi:10.1016/j.medj.2024.03.001 · Cited by 35

Oncogenic Pathways and Targeted Therapies in Ovarian Cancer

Lliberos, C., Richardson, G. E., & Papa, A. (2024) · Biomolecules · doi:10.3390/biom14050585 · Cited by 38

Fullerene‐Based Immunoregulatory Nanomaterials for Immunotherapy of Tumor and Immune‐Related Inflammatory Diseases

Zhen, M., Xu, Y. M., Wang, C., & Bai, C. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202409319 · Cited by 36

Bacteria‐Mediated Bismuth‐Based Nanoparticles Activate Toll‐Like Receptors for Breast Cancer Photothermal Immunotherapy

Xiao, S., Feng, C., Mu, M., Yu, W., Wang, X., Li, H., Chen, B., Fan, R., Chen, N., Han, B. R., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202410113 · Cited by 35

P-stalk ribosomes act as master regulators of cytokine-mediated processes

Dopler, A., Alkan, F., Malka, Y., van der Kammen, R., Hoefakker, K., Taranto, D., Kocabay, N., Mimpen, I. L., Ramirez, C. F. A., Malzer, E., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.039 · Cited by 37

Personalized nanovaccines for treating solid cancer metastases

Feng, T., Hu, J., Wen, J., Qian, Z., Che, G., Zhou, Q., & Zhu, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01628-4 · Cited by 36

Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020–2024)

Cheng, B., Lv, J., Xiao, Y., Song, C., Chen, J., & Shao, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117141 · Cited by 38

The emerging landscape of engineered bacteria cancer therapies

Ballister, E. R., Michels, A., Vincent, R. L., Kreindler, L., Chowdhury, S., Upadhaya, S., Saez-Ibañez, A. R., Tu, T., Gottweis, J., & Danino, T. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02623-x · Cited by 34

Perivascular Macrophages Regulate Blood Flow Following Tissue Damage

Vågesjö, E., Parv, K., Ahl, D., Seignez, C., Hidalgo, C. H., Giraud, A., Amoêdo‐Leite, C., Korsgren, O., Wallén, H., Juusola, G., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.318380 · Cited by 35

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas

dos Santos, L. V., Abrahão, C. M., & William, W. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.596290 · Cited by 36

Ferroptosis-apoptosis combined anti-melanoma immunotherapy with a NIR-responsive upconverting mSiO2 photodynamic platform

Li, D., Ren, J., Li, J., Zhang, Y., Lou, Y., Zhu, J., Liu, P., Chen, Y., Yu, Z., Zhao, L., et al. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.129557 · Cited by 35

Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?

Sumransub, N., Vantanasiri, K., Prakash, A., & Lou, E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.001 · Cited by 36

Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence

Farshbafnadi, M., Khoshbin, A. P., & Rezaei, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107876 · Cited by 39

Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients

van Wigcheren, G. F., de Haas, N., Mulder, T. A., Horrevorts, S. K., Bloemendal, M., Bree, S. H.-D., Mao, Y., Kiessling, R. W., van Herpen, C. M. L., Flórez‐Grau, G., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1935557 · Cited by 35

Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors’ Microenvironment

Kang, Y., Flores, L., Ngai, H. W., Cornejo, Y. R., Haber, T., McDonald, M., Moreira, D., Gonzaga, J. M., Abidi, W., Zhang, Y., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00139 · Cited by 35

Elucidating the Innate Immunological Effects of Mild Magnetic Hyperthermia on U87 Human Glioblastoma Cells: An In Vitro Study

Persano, S., Vicini, F., Poggi, A. D., Fernandez, J. L. C., Rizzo, G. M. R., Gavilán, H., Silvestri, N., & Pellegrino, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101668 · Cited by 37

Engineering DNA Nanostructures to Manipulate Immune Receptor Signaling and Immune Cell Fates

Tseng, C., Wang, W. X., Douglas, T. R., & Chou, L. Y. T. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101844 · Cited by 36

Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer

Yuan, M., Zhai, Y., Men, Y., Zhao, M., Sun, X., Ma, Z., Bao, Y., Yang, X., Sun, S., Liu, Y., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5479491 · Cited by 32

The emergence of nanoporous materials in lung cancer therapy

Radhakrishnan, D., Mohanan, S., Choi, G., Choy, J., Tiburcius, S., Trinh, H. T., Bolan, S., Verrills, N. M., Tanwar, P. S., Karakoti, A. S., et al. (2022) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2022.2052181 · Cited by 35

Integrative analysis of genomic and transcriptomic data of normal, tumour, and co‐occurring leukoplakia tissue triads drawn from patients with gingivobuccal oral cancer identifies signatures of tumour initiation and progression

Ghosh, A., Das, C., Ghose, S., Maitra, A., Roy, B., Majumder, P. P., & Biswas, N. K. (2022) · The Journal of Pathology · doi:10.1002/path.5900 · Cited by 39

Molecular Pathology of Gastric Cancer

Kim, M., & Seo, A. N. (2022) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2022.22.e35 · Cited by 38

Immune landscape and immunotherapy for penile cancer

Tang, Y., Hu, X., Wu, K., & Li, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1055235 · Cited by 37

Antigen discovery for the development of cancer immunotherapy

Ahn, R., Cui, Y., & White, F. M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101733 · Cited by 33

Nanoparticle-based immunotherapeutics: From the properties of nanocores to the differential effects of administration routes

Perez‐Potti, A., Rodríguez-Pérez, M., Polo, E., Pelaz, B., & del Pino, P. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114829 · Cited by 38

How can Cytokine-induced killer cells overcome CAR-T cell limits

Cappuzzello, E., Vigolo, E., D’Accardio, G., Astori, G., Rosato, A., & Sommaggio, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1229540 · Cited by 34

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study

Liu, H., Li, Y., Li, J., Zhang, Q., Wu, J., Li, X., Meng, L., Cao, S., & Li, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1199031 · Cited by 34

Review of the Potential of Probiotics in Disease Treatment: Mechanisms, Engineering, and Applications

Liu, M., Chen, J., Dharmasiddhi, I. P. W., Chen, S., Liu, Y., & Liu, H. (2024) · Processes · doi:10.3390/pr12020316 · Cited by 35

NETscape or NEThance: tailoring anti-cancer therapy

Mousset, A., Bellone, L., Gaggioli, C., & Albrengues, J. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.03.007 · Cited by 35

Neutrophils in glioma microenvironment: from immune function to immunotherapy

Sun, C., Wang, S., Ma, Z., Zhou, J., Ding, Z., Yuan, G., & Pan, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1393173 · Cited by 36

The future of cancer treatment: combining radiotherapy with immunotherapy

Dagar, G., Gupta, A., Shankar, A., Chauhan, R., Macha, M. A., Bhat, A. A., Das, D., Goyal, R., Bhoriwal, S. K., PANDITA, R. K., et al. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1409300 · Cited by 36

Understanding of Antigen and Phenotypic Plasticity Molecules for the Purpose of Cancer Immunotherapy

Malviya, R., Singh, A. K., & Yadav, D. (2024) · Apple Academic Press eBooks · doi:10.1201/9781003533955-4

Role of T cells in cancer immunotherapy: Opportunities and challenges

Ahmed, H., Mahmud, A. R., Siddiquee, M. F. R., Shahriar, A., Biswas, P., Shimul, M. E. K., Ahmed, S. Z., Ema, T. I., Rahman, N., Khan, M. A., et al. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.12.002 · Cited by 148

Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer

Ali, S., Arshad, M., Summer, M., Zulfiqar, M., Noor, S., Nazakat, L., & Javed, M. A. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251324896 · Cited by 10

T Lymphocyte–Based Cancer Immunotherapeutics

Borrie, A. E., & Vareki, S. M. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.010 · Cited by 27

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211